Theriva Biologics’ VCN-01 Trial Shows Prolonged Survival for Resistant Head & Neck Cancer Patients
Market Chameleon (Thu, 11-Jun 10:28 AM)
Theriva Biologics Builds Momentum with New VIRAGE Phase 2b VCN-01 Data Presentation Set for AACR 2026
Market Chameleon (Mon, 20-Apr 10:30 AM)
